Prihlásiť sa Zaregistrujte sa zadarmo

SMA 50 spoločnosti ProMIS Neurosciences

Aká je hodnota metriky SMA 50 spoločnosti ProMIS Neurosciences?

Hodnota metriky SMA 50 spoločnosti ProMIS Neurosciences, Inc. je CAD$7 -10.17%

Aká je definícia metriky SMA 50?



SMA 50 (Simple Moving Average 50) je priemerná cena akcie za posledných 50 dní vypočítaná ako nevážený priemer z predchádzajúcich 50 záverečných cien.

Simple moving average of 50 days for a stock is an unweighted moving average over the past 50 days. Moving averages will always exhibit a lag and the longer the period used for averaging the greater the lag will be. Because of the large amounts of data considered when calculating a long-term moving average, it takes a considerable amount of movement in the market to cause the moving average to change its course.

Using a moving average to confirm a trend in price is one of the most basic, yet effecting ways of using the indicator. Moving averages take into account what has already happened and a whole range of past events, which makes them such a good technical analysis tool for trend confirmations. Generally, a long-term moving average that is clearly on the upswing is a confirmation of a bullish trend. Conversely, a long-term moving average that is clearly on the downswing is a confirmation of a bearish trend.

SMA 50 spoločností v sektore Health Care sektor na TSX v porovnaní so spoločnosťou ProMIS Neurosciences

Čomu sa venuje spoločnosť ProMIS Neurosciences?

ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Firmy s metrikou sma 50 podobnou spoločnosti ProMIS Neurosciences